US · HQL · ASSET MANAGEMENT
Tekla Life Sciences Investors (HQL) intrinsic value and stock valuation
$15.38as of 2026-11-21 · Mkt cap 605.12M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Tekla Life Sciences Investors DCF and intrinsic value
InvestorsCraft values HQL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HQL’s statements →
Tekla Life Sciences Investors Graham Number
Graham Number: $34.45d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Gladstone Investment Corp. (GAIN) $13.41
- Eagle Point Credit Company Inc. (ECC) $2.42
- Gladstone Capital Corporation (GLAD) $17.03
- Crescent Capital BDC, Inc. (CCAP) $9.80
- Source Capital, Inc. (SOR) $45.46
- Barings Corporate Investors (MCI) $16.30
- CION Investment Corporation (CION) $5.55
- BlackRock TCP Capital Corp. (TCPC) $4.04
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $86.4M | $86.7M | $39.4M | $31.9M | $45M |
| Operating income | $85.6M | $85.3M | -$-5.24M | -$-104.6M | $64.5M |
| Net income | $85.6M | $85.3M | $22.4M | -$-104.6M | $64.5M |
| EPSd | $2.96M | $3.04M | $790K | -$-4.07M | $2.66M |
| Operating cash flow | -$-2.32M | — | $0.00 | $0.00 | $0.00 |
| Capital expenditure | -$0.00 | — | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-2.32M | — | $0.00 | $0.00 | $0.00 |
| Total assets | $515.4M | $460.6M | $402.6M | $414.7M | $534.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $11.1M | $1.34M |
| Net debt | -$-80K | -$0.00 | -$0.00 | $10K | $1.34M |
| Total equity | $513.7M | $459.7M | $401.9M | $397.9M | $523.4M |
| Cash and short-term investments | $80K | $0.00 | $15.2M | $0.00 | $0.00 |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $86.4M | $86.7M | $39.4M | $31.9M | $45M |
| Cost of revenue | $4.97M | $5.36M | $5.24M | $5.55M | $6.08M |
| Gross profit | $86.4M | $86.7M | $18.3M | $26.3M | $39M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | -$0.00 | $0.00 |
| Selling, general and administrative expenses | $740K | $1.33M | $900K | $1.08M | $840K |
| Other expenses | $50K | $60K | $270K | $280K | $310K |
| Operating expenses | $790K | $1.39M | $1.17M | $1.35M | $1.16M |
| Cost and expenses | $790K | $1.39M | $17M | $136.5M | -$-19.51M |
| Interest income | $350K | $1.04M | $200K | $50K | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $0.00 | $1.92M | $27.6M | $2.99M | $4.14M |
| Ebitda | $85.6M | $87.2M | $50M | -$-101.62M | $68.7M |
| Operating income | $85.6M | $85.3M | -$-5.24M | -$-104.6M | $64.5M |
| Total other income/expenses, net | $0.00 | $87.2M | $27.6M | $0.00 | -$-10K |
| Income before tax | $85.6M | $85.3M | $22.4M | -$-104.6M | $64.5M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $85.6M | $85.3M | $22.4M | -$-104.6M | $64.5M |
| Weighted average shares outstanding | $28.9M | $28.1M | $28.3M | $25.7M | $24.3M |
| Weighted average diluted shares outstanding | $28.9M | $28.1M | $28.3M | $25.7M | $24.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $80K | $0.00 | $15.2M | $0.00 | $0.00 |
| Net receivables | $1.14M | $230K | $5.04M | $620K | $150K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $1.25M | $280K | $5.05M | $620K | $140K |
| Property, plant and equipment, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $505.7M | $460.3M | $397.5M | $414.1M | $534M |
| Total non-current assets | $514.1M | $474.2M | $397.5M | $414.1M | $534M |
| Total assets | $515.4M | $460.6M | $402.6M | $414.7M | $534.2M |
| Accounts payable | $720K | $0.00 | $0.00 | $5.1M | $150K |
| Short-term debt | $0.00 | $0.00 | $0.00 | $11.1M | $10M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $5.09M | $0.00 |
| Total current liabilities | $720K | $890K | $0.00 | $5.1M | $10.8M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.01M | $890K | $670K | $11.7M | $10.8M |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $1.73M | $890K | $670K | $16.8M | $10.8M |
| Common stock | $300K | $280K | $270K | $260K | $250K |
| Retained earnings | $77.6M | $44.1M | -$-1.48M | $9.55M | $150.7M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $513.7M | $459.7M | $401.9M | $397.9M | $523.4M |
| Total investments | $514.1M | $477.5M | $412.8M | $414.1M | $534M |
| Total debt | $0.00 | $0.00 | $0.00 | $11.1M | $1.34M |
| Net debt | -$-80K | -$0.00 | -$0.00 | $10K | $1.34M |
Cash flow statement
| 2025 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net income | $85.6M | $22.4M | -$-100K | $60K | $120K |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-200K | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts receivable | $60K | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-2.32M | $0.00 | $0.00 | $0.00 | $0.00 |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $25.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-31.63M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-31.63M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net change in cash | $80K | $0.00 | -$0.00 | $0.00 | $0.00 |
| Cash at end of period | $80K | $0.00 | $0.00 | $0.00 | $1.12M |
| Operating cash flow | -$-2.32M | $0.00 | $0.00 | $0.00 | $0.00 |
| Capital expenditure | -$0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-2.32M | $0.00 | $0.00 | $0.00 | $0.00 |
Line items
Line items
Line items
About Tekla Life Sciences Investors
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
- CEO
- Daniel R. Omstead
- Employees
- 0
- Beta
- 0.71
Explore
Frequently asked questions
What is the intrinsic value of Tekla Life Sciences Investors (HQL)?
InvestorsCraft does not currently publish an intrinsic value for HQL. How the IC value is calculated.
Is HQL undervalued?
InvestorsCraft does not publish an undervaluation signal for HQL at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.